|
KMID : 0391319920020020233
|
|
Korean Journal of Biological Response Modifiers
1992 Volume.2 No. 2 p.233 ~ p.238
|
|
|
Combination of 5-Fluorouracil and Recombinant Interferon a-2B in Advanced Gastric Cancer
|
|
김진엽
이규형/이정신/서철원/이영상/민영일/안세현/박건춘/김석구
|
|
|
Abstract
|
|
|
Based on recent preclinical data suggesting synergism between 5-fluorouracil (5-FU) and interferon alpha (IFN-α) and clinical activity of the combination therapy in colon cancer, 14 patients with advanced gastric cancer were treated with
combination
therapy of 5-FU and recombinant interferon alpha-2b (rIFNα-2b) (Intron A, Schering, Kenilworth, NJ, U.S.A).
The maximum tolerated dose was 5-FU 750 mg/㎡/day given as a continuous infusion daily for 5 days followed by weekly bolus injection of the same initial daily dose, plus rIFNα-2b 5×10E6 U given subcutaneously 3 times weekly starting day 1 of
5-FU
infusion The dose-limiting toxicities were fatigue/weakness, diarrhea, and neurlolgic toxicities such as somnolence and confusion, The other common side effects were nausea, fever, leukocytopenia, thrombocytopenia, and the darkening of the skin,
Of
13
evaluable patients, 4 had a partial response (duration 6, 14, 24, and 28 weeks). These data suggest that combination therapy of 5-FU plus rIFNα-2b is tolerable and has manageable side effects inpatients with advanced gastric cancer. Further
Phase
II
study will be needed to define the antitumor activity of this combination.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|